Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value
$305.23−0.45 (-0.15%)
Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –
Krystal Biotech enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Krystal Biotech's enterprise value was $8.29B on Nov 11, 2026, against $5.59B a year earlier. Over the last 5 years it ranged from $929.03M to $10.12B, with a median of $3.83B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.29B | +29.3% |
| 2025 | Dec 31, 2025 | $6.41B | +63.8% |
| 2024 | Dec 31, 2024 | $3.92B | +33.4% |
| 2023 | Dec 29, 2023 | $2.94B | +78.8% |
| 2022 | Dec 30, 2022 | $1.64B | +35.5% |
| 2021 | Dec 31, 2021 | $1.21B | +35.3% |
| 2020 | Dec 31, 2020 | $896.01M | +18.6% |
| 2019 | Dec 31, 2019 | $755.30M | +329.5% |
| 2018 | Dec 31, 2018 | $175.84M | +219.0% |
| 2017 | Dec 29, 2017 | $55.13M | – |
See a number that looks wrong?